论文部分内容阅读
The new FDA drug-drug interaction (DDI) guidance permits waiver of clinical DDI trials if the assessment of DDI risks by Physiologically-based Pharmacokinetic (PBPK) modeling is low.In this presentation, the basics of PBPK modeling and simulation will be discussed.